Skelaxin (metaxalone) is a centrally acting skeletal muscle relaxant indicated as an adjunct to rest and physical therapy for the relief of discomfort associated with acute, painful musculoskeletal conditions. It works by depressing polysynaptic reflexes in the spinal cord and subcortical areas of the brain, leading to muscle relaxation without significantly impairing normal muscle function. Clinical studies demonstrate its efficacy in reducing muscle spasm and pain while maintaining a favorable side effect profile compared to older muscle relaxants. Proper patient selection and adherence to dosing guidelines are essential for optimal therapeutic outcomes.

Features

• Active ingredient: Metaxalone 800 mg
• Centrally acting skeletal muscle relaxant
• Tablet formulation for oral administration
• Typically prescribed as short-term therapy (up to 2-3 weeks)
• Demonstrated efficacy in clinical trials
• Lower incidence of sedation compared to other muscle relaxants
• Rapid onset of action (within one hour)
• Duration of effect: 4-6 hours

Benefits

• Provides effective relief from acute musculoskeletal pain and discomfort
• Reduces muscle spasm without complete muscle paralysis
• Allows improved participation in physical therapy programs
• Minimizes daytime sedation compared to alternative medications
• Facilitates restoration of normal range of motion
• Supports faster recovery from acute musculoskeletal injuries

Common use

Skelaxin is primarily prescribed for the management of acute musculoskeletal conditions characterized by muscle spasm and pain. These commonly include back pain, neck pain, muscle strains, sprains, and other traumatic injuries. It is typically used during the initial phase of treatment when muscle spasm significantly limits mobility and function. Healthcare providers often prescribe Skelaxin as part of a comprehensive treatment plan that includes rest, physical therapy, and other appropriate interventions. The medication is intended for short-term use, generally not exceeding two to three weeks, as most acute musculoskeletal conditions improve within this timeframe.

Dosage and direction

The recommended adult dosage of Skelaxin is 800 mg three to four times daily. Tablets should be taken whole with a full glass of water and may be administered with or without food, though taking with food may reduce the potential for gastrointestinal upset. The duration of therapy should not exceed two to three weeks, as recommended by clinical guidelines. Dosage adjustment may be necessary for elderly patients or those with hepatic impairment. Patients should not crush or chew tablets. It is essential to follow the prescribing physician’s instructions precisely and not to exceed the recommended dosage without medical supervision.

Precautions

Patients should exercise caution when operating machinery or driving until they understand how Skelaxin affects them, as it may cause drowsiness or dizziness. Alcohol consumption should be avoided during treatment, as it may enhance the sedative effects of the medication. Those with pre-existing liver conditions require careful monitoring, as metaxalone is metabolized hepatically. Elderly patients may be more sensitive to the effects of muscle relaxants and should be monitored closely for adverse reactions. Patients should inform their healthcare provider of all medications they are taking, including over-the-counter drugs and supplements. Proper hydration is recommended during therapy.

Contraindications

Skelaxin is contraindicated in patients with known hypersensitivity to metaxalone or any components of the formulation. It should not be used in patients with significantly impaired hepatic function or history of drug-induced hemolytic anemia. The medication is contraindicated in patients with acute intermittent porphyria. Use during pregnancy should be avoided unless clearly necessary, as safety during pregnancy has not been established. Skelaxin is not recommended for children under 12 years of age due to insufficient safety data. Patients with renal impairment should use caution and may require dosage adjustment.

Possible side effect

Common side effects include dizziness, drowsiness, nausea, vomiting, and nervousness or irritability. These effects are generally mild and often diminish with continued therapy. Less frequently reported side effects include headache, gastrointestinal discomfort, and rash. Serious but rare adverse reactions may include hypersensitivity reactions, hemolytic anemia, and liver enzyme elevations. Patients should discontinue use and seek immediate medical attention if they experience signs of allergic reaction (hives, difficulty breathing, swelling), jaundice, or unusual fatigue. Most side effects are dose-related and may be minimized by proper dosing.

Drug interaction

Skelaxin may enhance the effects of other central nervous system depressants, including alcohol, benzodiazepines, opioids, and sedative antihistamines. Concurrent use with monoamine oxidase inhibitors (MAOIs) may increase the risk of adverse reactions. Medications that affect liver enzymes, particularly CYP inhibitors, may alter metaxalone metabolism. Anticholinergic drugs may compound certain side effects. Patients should inform their healthcare provider of all prescription medications, over-the-counter drugs, and herbal supplements they are taking to avoid potential interactions.

Missed dose

If a dose is missed, it should be taken as soon as remembered unless it is nearly time for the next scheduled dose. In that case, the missed dose should be skipped, and the regular dosing schedule resumed. Patients should never double the dose to make up for a missed one. Maintaining consistent dosing intervals helps maintain stable blood levels of the medication and ensures consistent therapeutic effect. If multiple doses are missed, patients should contact their healthcare provider for guidance.

Overdose

Symptoms of Skelaxin overdose may include severe drowsiness, confusion, loss of consciousness, respiratory depression, and seizures. In case of suspected overdose, immediate medical attention should be sought. Treatment is primarily supportive and may include gastric lavage if ingestion was recent, activated charcoal administration, and monitoring of vital signs. Respiratory support may be necessary in severe cases. There is no specific antidote for metaxalone overdose. Patients should be monitored for at least 24 hours due to the potential for delayed effects.

Storage

Store Skelaxin tablets at room temperature (20-25°C or 68-77°F) in their original container with the lid tightly closed. Protect from moisture and excessive heat. Keep out of reach of children and pets. Do not store in bathroom cabinets where moisture levels may be high. Properly discard any expired or unused medication according to FDA guidelines or through medication take-back programs. Do not flush medications down the toilet unless specifically instructed to do so.

Disclaimer

This information is provided for educational purposes only and does not constitute medical advice. Individual patient needs may vary, and only a qualified healthcare professional can determine appropriate treatment. Patients should consult with their physician before starting or changing any medication regimen. The prescribing information provided here may not include all possible uses, directions, precautions, or interactions.

Reviews

Clinical studies have demonstrated Skelaxin’s efficacy in managing acute musculoskeletal conditions, with many patients reporting significant improvement in pain and muscle spasm. Healthcare providers often note its favorable side effect profile compared to other muscle relaxants, particularly regarding reduced sedation. Patient satisfaction surveys indicate improved quality of life and functional capacity during treatment. However, individual responses may vary, and some patients may experience inadequate relief or undesirable side effects. Long-term safety data beyond three weeks of continuous use are limited.